[{"indications": "Indications\u00a0adjunct in the treatment of female infertility (under specialist\r\nsupervision)", "name": "GANIRELIX", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.2 Drugs affecting gonadotrophins"], "side-effects": "Side-effects\u00a0nausea, headache, malaise, injection-site reactions; very rarely hypersensitivity reactions including rash, facial\r\noedema, and dyspnoea also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/89834.htm", "doses": ["By subcutaneous injection preferably into\r\nthe upper leg (rotate injection sites to prevent lipoatrophy), 250\u00a0micrograms\r\nin the morning (or each afternoon) starting on day 5 or day 6 of ovarian\r\nstimulation with gonadotrophins; continue throughout administration\r\nof gonadotrophins including day of ovulation induction (if administering\r\nin afternoon, give last dose in afternoon before ovulation\r\ninduction)"], "pregnancy": "Pregnancy\u00a0avoid in confirmed pregnancy\u2014toxicity in animal studies"}]